Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,730 recruiting studies in this area right now.
By phase
- Not applicable9,856
- Phase 24,487
- Phase 12,738
- Phase 1/Phase 21,696
- Phase 31,409
- Phase 2/Phase 3281
- Phase 4263
Top conditions
- Breast Cancer1,233
- Prostate Cancer660
- Cancer655
- Colorectal Cancer499
- Lung Cancer430
- Ovarian Cancer341
- Multiple Myeloma330
- Gastric Cancer302
- Pancreatic Cancer295
- Acute Myeloid Leukemia290
- Hepatocellular Carcinoma285
- Solid Tumor256
- Advanced Solid Tumor254
- Cervical Cancer233
- Head and Neck Cancer229
- Endometrial Cancer207
- Advanced Solid Tumors196
- Esophageal Cancer196
Leading sponsors
- M.D. Anderson Cancer Center452
- Fudan University317
- National Cancer Institute (NCI)291
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center289
- Mayo Clinic237
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center146
- AstraZeneca131
- University Health Network, Toronto125
Where studies are running
- California1,432
- Texas644
- Arizona514
- Florida437
- Alabama419
- New York410
- Massachusetts342
- Maryland331
- New Jersey267
- Pennsylvania237
Recruiting studies20,730 total
- NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT06609005RecruitingPhase 1/Phase 2
Study of INV-9956 for advanced prostate cancer
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06609304RecruitingPhase 4
CAR T-cell therapy after first treatment for high-risk lymphoma
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
Zhengzhou, HenanAges 18–70 - NCT06609551RecruitingPhase 3
ctDNA-guided chemo choice for elderly colon cancer patients
This trial tests whether using a ctDNA blood test can help choose the best chemotherapy after colon cancer surgery for people aged 70–80. It aims to make treatment more personalized and reduce side effects.
Hangzhou, ZhejiangAges 70–80 - NCT06609850Recruiting
Comparing TACE plus lenvatinib with or without ablation for recurrent liver cancer
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
Beijing, None SelectedAges 18–75 - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75 - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT06610539Recruiting
Magnetic tracer for sentinel node biopsy in breast cancer
This study tests a magnetic tracer call Magtrace to help find and remove the first lymph node (sentinel node) during breast cancer surgery. The goal is to see if it works well for people having breast-conserving surgery.
Chapel Hill, North CarolinaAges 18 years+ - NCT06610565Recruiting
Fasting-mimicking diet for breast cancer side effects
This study tests if a special diet that mimics fasting can help reduce side effects from hormone therapy (aromatase inhibitors) in women with breast cancer. The diet is a low-calorie meal plan designed to lower cholesterol and improve well-being.
Milan, ItalyAges 18 years+ - NCT06610604Recruiting
Thyroid nodule treatment and quality of life study
This study looks at how thyroid nodules affect your daily life and feelings after treatment. It compares quality of life in people who had microwave ablation versus those who had thyroid surgery.
Beijing, Beijing MunicipalityAges 18–70 - NCT06610825RecruitingPhase 2
Enhertu for prostate cancer resistant to hormone therapy
This trial is testing a drug called Enhertu for men whose prostate cancer has spread and is no longer responding to hormone treatments. You may join if you have a tumor sample that can be tested for a protein called HER2.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06610851Recruiting
Monitoring low-grade brain tumors with a blood test
This study is looking at whether a simple blood test that checks for tiny molecules (called miRNAs) can help monitor people with slow-growing brain tumors. If you had surgery for a grade 2 or 3 glioma at Caen University Hospital and are still being followed there, this study might be for you.
CaenAges 18 years+ - NCT06611020Recruiting
Vaccine after cone surgery for cervical dysplasia
This trial tests whether giving an HPV vaccine after a cone biopsy (a surgery to remove abnormal cells from the cervix) helps prevent the HPV-related disease from coming back. It may be an option for patients who have had treatment for cervical dysplasia and have not been vaccinated against HPV before.
Milan, LombardyAges 18 years+ - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06611072Recruiting
Boosting immune response in ovarian cancer surgery
This study examines how to improve the immune system's response during ovarian cancer surgery, potentially helping the body fight the cancer better. It compares patients with ovarian cancer to women having surgery for non-cancerous conditions.
Eindhoven, North BrabantAges 18 years+ - NCT06611150RecruitingPhase 1
Chemo and radiation for advanced nasopharyngeal cancer
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
Guangzhou, GuangdongAges 18–70 - NCT06611345Recruiting
Tumor-treating fields with immunotherapy and chemo for bile duct cancer
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
HefeiAges 18–75 - NCT06611813RecruitingPhase 2
Chemo plus immunotherapy for HR+/HER2- breast cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
HangzhouAges 18–75 - NCT06612034Recruiting
Prostate cancer provider survey on care gaps
This study surveys doctors who treat prostate cancer to understand differences in care. It aims to find ways to make care more equal for all patients.
Ankara, AnkaraAges Any age - NCT06612047Recruiting
Comparing high-field and ultra-high-field MRI for prostate cancer diagnosis
This study compares two types of MRI scans – one at 3.0 Tesla and one at 5.0 Tesla – to see which is better at finding prostate cancer. If you are scheduled for a prostate biopsy, you may be asked to get both scans to help improve detection.
Hefei, AnhuiAges 18 years+ - NCT06612281RecruitingPhase 2
Testing a new screening tool for colorectal cancer in people with negative FIT results
This trial tests a new device called Gixam to see if it can help find colorectal cancer in people who recently had a normal FIT test (a stool test for blood). You may be able to join if you are between 45 and 85 years old and are already scheduled for a routine screening colonoscopy.
Portland, OregonAges 45–85 - NCT06612580RecruitingEarly Phase 1
New PET scan agent for prostate cancer
This study tests a new imaging agent called 68Ga-AAZTA-NI-093 for a special PET/CT scan that might help see prostate cancer more clearly. It is for people with prostate cancer, whether they've had treatment or not.
Fuzhou, FujianAges 18–80 - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,730 recruiting oncology studies from the U.S. registry right now, out of 32,266 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.